Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 471 - Interview with Tim Moore and Susan Chappelle, Co-CEO’s of Havn Life Sciences (CSE: $HAVN.C)
Today’s
podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed
cannabis cultivation and distribution company in Switzerland
Delta, Kelowna, BC, September 23, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/092320-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/09231Interview-HAVN.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
Today’s podcast is
sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully
licensed cannabis cultivation and distribution company in Switzerland, for
recreational tobacco products and medical CBD oils. The Company's facilities
for producing cannabis are based in Dietikon, Switzerland, and contain the art
surveillance equipment to enable an around the clock webcast. Cannabis Suisse
grows high quality, organic cannabis with sustainable, all-natural principles.
The Company's products are laboratory tested to ensure the end users have
access to a standardized, safe and consistent product. Cannabis Suisse
proprietary trademarked MoldStandard is a quantitative microbiology method for
analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse
proprietary trademarked CannaMec is a method for quantifying and removing
residual solvents during packaging and storage of CBD products. Cannabis Suisse
Corp. currently sells via a distribution network of Swiss retailers and online
shops, under the retail brand Alpine Cannabis.
In
today’s podcast Investorideas interview Tim Moore and Susan Chappelle, the
Co-CEO’s of Havn Life Sciences Inc. (CSE :
HAVN), a biotechnology company focused on unlocking human
potential using evidence-informed research, and developing standardized
psychoactive compounds derived from plants and fungi. We discuss the company’s
most recent
announcement that, on August 31, 2020, its wholly-owned
subsidiary, HAVN Research Inc., was granted a Section 56 exemption by Health
Canada, pursuant to which it now has the ability to possess certain amounts of
pure psilocybin for scientific purposes, specifically for the research and
development of quality control methods.
Havn Life intends to immediately
begin work on experiments with the objective of developing a set of methods for
the safe, standardized, quality-controlled production of medical compounds
extracted from the Psilocybe spp. mushroom.
"We are thrilled to be among
the first to receive permission from the Canadian government to begin work with
psilocybin", stated Tim Moore, Co-CEO of Havn Life. "This important
milestone will enable Havn to begin working toward creating method-validation
and analytical chemistry to standardize methods for quality control and testing
of these substances."
"Having access to compounds is
essential in order to further research in the medical field. This is the start
of our journey into developing standardized protocols to ensure that as this
industry grows, we understand efficient new methodology", stated Susan
Chapelle, Havn Life Co-CEO, noting the advent of new technology and variables
in extraction have changed significantly in the last decade.
Moore and Chappelle went on to
discuss the company’s two pronged approach to the psychedelic market as well as
what separates them from other competitors entering this new landscape.
“Haven Life is an exciting
opportunity in that we are focusing on the supply chain. Basically there have
been very few companies focusing on supply chain. Most of the research going on
right now is with synthetics, but the people using these compounds use them in
their natural forms. Creating a natural compound library so researchers can
extract the compounds they need to make sure that the human performance and
outcomes are stable and repeatable is such an important space to be in. Our team
also has strong retail, scientific and policy experience makes us well attuned
to the regulatory space as well. We’ve placed ourselves in the supply chain as
opposed to the end user clinic space because we think this a much better
opportunity to ensure safe, standardized and effective compounds,” commented
Susan Chappelle.
Chappelle also went on to discuss
how this industry aims to deal with the very unique and subjective effects and
experience of psilocybin saying, “If you’re picking a mushroom from the woods,
you have no idea how much psilocybin is in that mushrooms. Having the
researchers have safe standardized compounds and dosing of the effective
ingredients and then be in a clinic, a safe environment, I think the landscape
over the next few years is going to rapidly change.”
Tim and Susan went on to discuss in
more detail the importance of creating a standardized supply chain, the
importance of working with natural whole plant compounds versus synthetic
compounds as well as the future of psilocybin research.
To find out more about Havn Life
Sciences visit their website here.
Once again, today’s podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. Disclosure: Cannabis
Suisse Corp. (OTC: CSUI ),is
a paid featured company on Investorideas.com More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
No comments:
Post a Comment